Abstracts tagged "tumor necrosis factor (TNF) and vaccines"

Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Karen Boyle³, Lynette Keyes-Elstein³, Beverly Welch⁴, Ellen Goldmuntz⁵ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…
Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Patrick Durez¹, Pedro Miranda², Antoaneta Toncheva³, Alberto Berman Sr.⁴, Oscar L. Rillo⁵, Yves Boutsen⁶, Tatjana Kehler⁷, Eugenia Mociran⁸, LiAn Soto Saez⁹, Bruno Fautrel¹⁰, Xavier Mariette¹¹, Panayot Solakov¹², Eleonora Lucero¹³, Tonko Vlak¹⁴, Simeon Grazio¹⁵, Ksenija Mastrovic¹⁶, Rodica Chiriac¹⁷, Géraldine Grouard-Vogel¹⁸, Olivier Dhellin¹⁸, Stéphane Ouary¹⁸, Pierre Vandepapeliere¹⁸ and Marie-Christophe Boissier¹⁹, ¹Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶UCL Mont-Godinne, Godinne, Belgium, ⁷Thalassotherapia Opatija, Opatija, Croatia, ⁸Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ⁹Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹²Plovdiv, Diagnostic and Consulting Center, Plovdiv, Bulgaria, ¹³Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, ¹⁴University Hospital Split, Split, Croatia, ¹⁵Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁶Clinical Hospital Sveti Duh, Zagreb, Croatia, ¹⁷Rehabilitation clinical Hospital Iasi, Iasi, Romania, ¹⁸NEOVACS SA, Paris, France, ¹⁹Dept of Rheumatology, Hopital Avicenne, Bobigny, France
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].